User profiles for Stephen Lockhart
 | Stephen LockhartVice President, Pfizer Vaccine Clinical R&D Verified email at pfizer.com Cited by 27425 |
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, J Absalon, A Gurtman, S Lockhart… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, J Absalon, A Gurtman, S Lockhart… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents
…, A Gurtman, J Absalon, S Lockhart… - … England Journal of …, 2021 - Mass Medical Soc
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, J Absalon, A Gurtman, S Lockhart… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
…, C Sabharwal, A Gurtman, S Lockhart… - … England Journal of …, 2022 - Mass Medical Soc
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
[HTML][HTML] Efficacy of a pneumococcal conjugate vaccine against acute otitis media
…, P Karma, R Kohberger, S Lockhart… - … England Journal of …, 2001 - Mass Medical Soc
Background Ear infections are a common cause of illness during the first two years of life.
New conjugate vaccines may be able to prevent a substantial portion of cases of acute otitis …
New conjugate vaccines may be able to prevent a substantial portion of cases of acute otitis …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] Bivalent Omicron BA. 1–Adapted BNT162b2 booster in adults older than 55 years
…, SJ Thomas, O Diya, S Lockhart… - … England Journal of …, 2023 - Mass Medical Soc
Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …
[HTML][HTML] SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
…, J Absalon, A Gurtman, S Lockhart… - … England Journal of …, 2021 - Mass Medical Soc
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
[HTML][HTML] Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
…, BS Landry, TJ Scriba, MA Snowden, S Lockhart… - The Lancet, 2013 - thelancet.com
Background BCG vaccination provides incomplete protection against tuberculosis in infants.
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …